Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 1455 results for do not do recommendations

  1. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    17 February 2021
    View recommendations

    Sections for TA673

  2. What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    Recommendation ID CG184/4 Question What specialist management is effective for people whose symptoms do not respond to PPIs...

    Research recommendation
    Published
    15 November 2019

  3. Additional assessments:- Do additional assessments (for IQ, language ability and motor ability) improve accuracy in diagnosing autism among preschool children (younger than 5 years) compared with signs and symptoms alone?

    Recommendation ID CG128/3 Question Additional assessments:- Do additional assessments (for IQ, language ability and motor...

    Research recommendation
    Published
    9 June 2015

  4. Other specialist management:- What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    Recommendation ID CG184/4 Question Other specialist management:- What specialist management is effective for people whose symptoms...

    Research recommendation
    Published
    9 June 2015

  5. What types of information provision, including mass-media campaigns, are effective and cost effective in preventing skin cancer in the UK? What factors influence effectiveness and cost effectiveness? •Does effectiveness and cost effectiveness vary for different population groups? (Groups could be defined by gender, age, race/ethnicity, socioeconomic status or other characteristics such as lifestyle and at-risk behaviours.) • What impact do they have on knowledge, attitudes, awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors that aid or hinder the success of these interventions or campaigns, including for different population groups? In particular, how does changing attitudes to sunbathing and tanning – and perceptions of the risk of skin cancer –influence success? Do attitudes vary for different population groups?

    Recommendation ID PH32/2 Question What types of information provision, including mass-media campaigns, are effective and cost effective

    Research recommendation
    Published
    9 June 2015

  6. Information for the public on medicines

    that they can manufacture the medicine to the required quality. At NICE we do not license medicines - you can find out more about the...

  7. Antisocial behaviour and conduct disorders in children and young people (QS59)

    This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    17 April 2014
    View quality statements

    Sections for QS59

  8. Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical outcomes in women who choose and women who do not choose to have risk-reducing surgery. [new 2013]

    Recommendation ID CG164/5 Question Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical

    Research recommendation
    Published
    9 June 2015

  9. What is the clinical and cost effectiveness of fitting amplification devices(s) in people with tinnitus who have hearing loss but no perceived hearing difficulties?

    Recommendation ID NG155/12 Question What is the clinical and cost effectiveness of fitting amplification devices(s) in people with...

    Research recommendation
    Published
    17 March 2020

  10. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 November 2019
    View recommendations

    Sections for TA612

  11. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

    Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA374

  12. Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other approaches to care (for example other systemic non-biological or biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk?

    Recommendation ID CG153/2 Question Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other...

    Research recommendation
    Published
    9 June 2015

  13. Familial hypercholesterolaemia: identification and management (CG71)

    This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.

    Clinical guideline
    Last updated
    4 October 2019
    View recommendations

    Sections for CG71

  14. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA425

  15. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST22)

    Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.

    Highly specialised technologies guidance
    Published
    22 February 2023
    View recommendations

    Sections for HST22